baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

REGENERON PHARMACEUTICALS/ US75886F1075 /

2024-11-08 5:32:26 PM	Chg. +9.20	Volume	Bid5:32:26 PM	Ask5:32:26 PM	Market Capitalization	Dividend Y.	P/E Ratio
770.40EUR	+1.21%	0 Turnover: -	-Bid Size: -	-Ask Size: -	84.94 bill.EUR	-	-

GlobeNewswire 08-28 Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

GlobeNewswire 08-26 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...

GlobeNewswire 08-26 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 08-21 Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewswire 08-15 Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...

GlobeNewswire 08-15 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimi...

GlobeNewswire 08-12 Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...

GlobeNewswire 08-08 Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ...

GlobeNewswire 08-07 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

GlobeNewswire 08-05 BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update

GlobeNewswire 08-01 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 07-31 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

GlobeNewswire 07-23 Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 07-23 BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

GlobeNewswire 07-16 Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

GlobeNewswire 07-10 Regeneron Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm

GlobeNewswire 07-07 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 07-03 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 07-03 Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

GlobeNewswire 06-30 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

GlobeNewswire 06-28 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 06-27 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 06-26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 06-26 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 06-22 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...

REGENERON PHARMACEUTICALS/ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.